US Stock MarketDetailed Quotes

LPCN Lipocine

Watchlist
  • 3.4700
  • -0.0900-2.53%
Close Mar 26 16:00 ET
  • 3.4700
  • 0.00000.00%
Post 20:01 ET
18.57MMarket Cap-1735.00P/E (TTM)

About Lipocine Company

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Company Profile

SymbolLPCN
Company NameLipocine
Listing DateMar 21, 2014
Founded2011
CEOMr. Mahesh V. Patel, PhD
MarketNASDAQ
Employees16
Fiscal Year Ends12-31
Address675 Arapeen Drive,Suite 202
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84108
Phone1-801-994-7383

Company Executives

  • Name
  • Position
  • Salary
  • Mahesh V. Patel, PhD
  • Director, President, Chief Executive Officer and Principal Financial Officer
  • --
  • Krista Fogarty
  • Principal Accounting Officer and Corporate Controller
  • --
  • Nachiappan Chidambaram, PhD
  • Senior Vice President, Research and Development
  • --
  • Dr. Spyros Papapetropoulos, PhD
  • Lead Independent Director and Chairman of the Board
  • --
  • John W. Higuchi, M.B.A.
  • Director
  • --
  • Dr. Jill M. Jene, M.B.A.,PhD
  • Independent Director
  • --
  • Jeffrey A Fink, M.B.A.
  • Independent Director
  • --
  • Dr. Richard Dana Ono, PhD
  • Independent Director
  • --

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More